Tevogen AI Initiative for Immunotherapy
Source: aithority.com
Tevogentoday shared details with stockholders regarding its artificial intelligence initiative, Tevogen.AI™. The goal of Tevogen.AI™ is to incorporate advanced machine learning and predictive modeling into Tevogen Bio’s ExacTcell™ technology to improve target identification and pre-clinical processes. This is expected to strengthen the company’s pipeline of immunotherapies, accelerate clinical timelines, and reduce development costs.
Tevogen.AI Technologies
Tevogen.AI has two proprietary technologies, each with patents pending. The company intends to broaden its AI initiative with applications beyond Tevogen Bio. In anticipation of future growth, Tevogen is expanding its headquarters to include facilities for the Tevogen.AI team.
Tevogen CEO, Dr. Ryan Saadi, stated that Tevogen.AI’s vision extends beyond therapy development and is expected to have an impact across multiple sectors of healthcare. He also applauded the leadership team at Tevogen.AI and its strategic partners for their contributions.
Strategic Partnerships
Microsoft
Microsoft provides AI expertise, cloud computing infrastructure (Azure), and scientific resources to help speed up drug discovery.
Databricks
Databricks delivers data engineering and analytics capabilities to refine Tevogen’s AI models and improve predictive accuracy.
Proprietary Technology
PredicTcell™
PredicTcell™ uses AI tools to predict immunologically active peptide complexes and their interactions with T cell receptors to drive precision in immunotherapy treatments. The PredicTcell platform uses algorithms for in-silico predictions for candidate selection across diseases. It improves with each prediction through model tuning, expanding the understanding of T cell receptor bindings, shortening the in-vivo process and expanding Tevogen Bio’s pipeline. Tevogen.AI has developed a terabyte-scale database that processes millions of protein and peptide interactions across diseases and the human genome.
AdapTcell™
AdapTcell™ uses algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells. AdapTcell is expected to enhance the understanding of immune responses and open new therapeutic avenues. AdapTcell algorithms perform experiments unlocking insights into genetics and proteomics, building an HLA specificity map. Tevogen.AI intends to expand into clinical trial patient identification using PredicTcell and AdapTcell to drive efficiency, reduce costs and deliver targeted results.
Tevogen will continue to provide updates on the progress of Tevogen.AI.
This press release contains forward-looking statements regarding Tevogen’s plans for its research and manufacturing capabilities, expectations regarding future growth, expectations regarding the healthcare and biopharmaceutical industries, and Tevogen’s development of product candidates. These statements are subject to risks and uncertainties that may cause actual results to differ.